Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 7
Submit an article Journal homepage
577
Views
6
CrossRef citations to date
0
Altmetric
Hematology

Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study

Changgang LiDepartment of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China;
,
Xinsheng ZhangHemophilia Treatment Centre, Shandong Blood Centre, China;
,
Yongqiang ZhaoDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China; Correspondence[email protected]
,
Runhui WuHematology/Oncology Centre, Beijing Children’s Hospital, Capital Medical University, Beijing, China;
,
Qun HuDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (HUST), Hankou, Wuhan, China;
,
Weiqun XuDepartment of Hematology, The Children’s Hospital, Zhengjiang University School of Medicine, Hangzhou, China;
,
Jing SunDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou, China;
,
Renchi YangThrombosis and Hemostasis Centre, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;
,
Xiaojing LiDepartment of Hematology, Chengdu Women & Children’s Central Hospital, Chengdu, China;
,
Rongfu ZhouDepartment of Hematology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China;
,
Shinmei LianDepartment of Hematology, Dalian Municipal Central Hospital, Dalian Medical University, Dalian, China;
,
Jian GuDepartment of Hematology, Northern Jiangsu People’s Hospital, Clinical Medical School of Yangzhou University, Yangzhou;
,
Junde WuBayer HealthCare Pharmaceuticals Inc., Bayer Centre, Beijing, China
&
Qingsong HouBayer HealthCare Pharmaceuticals Inc., Bayer Centre, Beijing, China
 show all
Pages 1223-1230 | Received 15 Dec 2016, Accepted 23 Feb 2017, Published online: 25 Apr 2017

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Runhui Wu, Jing Sun, Weiqun Xu, Qun Hu, Wenqian Li, Jianwen Xiao, Feng’e Yang, Xiaojing Zeng, Yun Zeng, Jianfeng Zhou, Irina Matytsina, Sali Zhang, Michael Pluta & Renchi Yang. (2020) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. Therapeutics and Clinical Risk Management 16, pages 567-578.
Read now

Articles from other publishers (5)

Luying Zhang, Peng Zhang & Wen Chen. (2023) Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe hemophilia A in China: using real-world data. Orphanet Journal of Rare Diseases 18:1.
Crossref
Xiaoning He, Xu Wang, Chaohui Dong, Mingyue Zhao & Jing Wu. (2022) The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033. Haemophilia 28:5, pages 726-736.
Crossref
Jing Sun, Xuan Zhou & Nan Hu. (2021) Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review. Orphanet Journal of Rare Diseases 16:1.
Crossref
Xuewen Song, Jia Zhong, Feng Xue, Lingling Chen, Huiyuan Li, Donghui Yuan, Jipan Xie, Jun Shi, Lei Zhang, Eric Q. Wu & Renchi Yang. (2020) An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies. Haemophilia 27:1.
Crossref
Novie A. Chozie, Fitri Primacakti, Djajadiman Gatot, Rahajuningsih D. Setiabudhy, Angela B. M. Tulaar & Marcel Prasetyo. (2019) Comparison of the efficacy and safety of 12‐month low‐dose factor VIII tertiary prophylaxis vs on‐demand treatment in severe haemophilia A children. Haemophilia 25:4, pages 633-639.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.